WATERTOWN, Mass.--(BUSINESS WIRE)--
pSivida Corp. (NASDAQ:PSDV; ASX:PVA), a leader in developing sustained
release, drug delivery products for treating eye diseases, today
announced that it has signed two funded technology evaluation agreements
with a leading global pharmaceutical company. The agreements will each
evaluate the use of pSivida's Durasert™ technology to deliver a specific
compound to treat a significant ophthalmic disease.
"We are very pleased to be working with this leading global
pharmaceutical company," said Dr. Paul Ashton, president and CEO of
pSivida. "Our strategy includes partnering product development with
market leaders in appropriate circumstances, allowing us to expand our
reach beyond our own product development. This opportunity fits that
criteria, and we are excited about the potential products."
About pSivida Corp.
pSivida Corp. (www.psivida.com)
headquartered in Watertown, MA, is a leader in the development of
sustained release, drug delivery products for treating eye diseases.
pSivida developed three of only four back of the eye implants approved
by the FDA (Vitrasert® and Retisert®, licensed to Bausch & Lomb; and
ILUVIEN®, licensed to Alimera Sciences). pSivida's lead product
candidate, Medidur™ for the treatment of posterior uveitis, is currently
in pivotal phase III clinical trials. pSivida is also involved in the
development of products focused on ocular and systemic delivery of
biologics and drugs to treat wet and dry age-related macular
degeneration (AMD), glaucoma, osteoarthritis and other diseases. These
products are in preclinical development utilizing pSivida's two core
technology platforms: Durasert™ and/or Tethadur™.
SAFE HARBOR STATEMENTS UNDER THE PRIVATE SECURITIES LITIGATION REFORM
ACT OF 1995: Various statements made in this release are
forward-looking, and are inherently subject to risks, uncertainties and
potentially inaccurate assumptions. All statements that address
activities, events or developments that we intend, expect or believe may
occur in the future are forward-looking statements. These forward
looking statements include, but are not limited to, statements regarding
the regulatory path to obtain regulatory approval of Medidur in the
United States, the benefit we may receive from our share of net profits
on sales of ILUVIEN, the timing of the filing of an NDA for Medidur,
FDA's willingness to accept the NDA, the timing of results of our phase
III trial of Medidur, and the length of time our capital resources will
last and be sufficient to fund our planned development programs. Some of
the factors that could cause actual results to differ materially from
the anticipated results or other expectations expressed, anticipated or
implied in our forward-looking statements include uncertainties with
respect to: ability to achieve profitable operations and access to
capital; fluctuations in operating results; further impairment of
intangible assets; decline in Retisert royalties; successful
commercialization of, and receipt of revenues from, ILUVIEN for DME;
effect of pricing and reimbursement decisions on sales of ILUVIEN for
DME; consequences of fluocinolone acetonide side effects; number and
cost of clinical trials and data necessary to support an NDA for,
approval by Indian regulators of the trial design for, timing of filing
the NDA for, and regulatory approval and successful commercialization
of, Medidur; delays in completion of clinical trials; increases in cost
of clinical trials; changes in, or misunderstandings with respect to,
FDA guidance on required clinical trials; development of the Latanoprost
Product and any exercise by Pfizer of its option; ability of Tethadur to
successfully deliver large biologic molecules and to develop products
using it; ability to successfully develop product candidates, complete
clinical trials and receive regulatory approvals; ability to market and
sell products; success of current and future license agreements;
termination of license agreements; effects of competition and other
developments affecting sales of products; market acceptance of products;
effects of guidelines, recommendations and studies; protection of
intellectual property and avoiding intellectual property infringement;
retention of key personnel; product liability; industry consolidation;
compliance with environmental laws; manufacturing risks; risks and costs
of international business operations; legislative or regulatory changes;
volatility of stock price; possible dilution; absence of dividends; and
other factors described in our filings with the SEC. You should read and
interpret any forward-looking statements together with these risks.
Should known or unknown risks materialize, or should underlying
assumptions prove inaccurate, actual results could differ materially
from past results and those anticipated, estimated or projected in the
forward-looking statements. You should bear this in mind as you consider
any forward-looking statements. Our forward-looking statements speak
only as of the dates on which they are made. We do not undertake any
obligation to publicly update or revise our forward-looking statements
even if experience or future changes makes it clear that any projected
results expressed or implied in such statements will not be realized.
Follow pSivida on social media:
Twitter: https://twitter.com/pSividaCorp
Facebook: https://www.facebook.com/pages/PSivida-Corp/544893792199562
LinkedIn: http://www.linkedin.com/company/psivida
Google+: https://plus.google.com/u/0/b/113754643626984244726/113754643626984244726/posts
The President's Blog: http://www.thechairmansblog.com/paul-ashton
For more information on pSivida, visit www.psivida.com.
Martin E. Janis & Company, Inc.
Beverly Jedynak
President
+1
312 943 1123
M: +1 773 350 5793
bjedynak@janispr.com
Source: pSivida Corp.
News Provided by Acquire Media
